BRAF and melanoma: This cohort study integrates bulk and single-cell genomic analysis of resected melanoma brain metastases with detailed clinical follow-up to identify BRAF V600 alteration status as an important biomarker associated with an altered intracranial tumor microenvironment and decreased response to immunotherapy.